126 related articles for article (PubMed ID: 37394400)
1. Correlates of one-year mortality among patients living with HIV according to the stratification level of the pharmaceutical care model.
Contreras-Macías E; Robustillo-Cortés MLA; Morillo-Verdugo R
Enferm Infecc Microbiol Clin (Engl Ed); 2024; 42(6):302-307. PubMed ID: 37394400
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of quality of life in patients living with HIV infection through pharmaceutical care according to CMO methodology vs. conventional follow-up. MAS-VIH project].
Martínez Sesmero JM; Margusino Framiñan L; Gimeno Gracia M; Áreas Del Águila V; Navarro Aznares H; Huertas Fernández MJ; Molina Cuadrado E; Díaz Ruiz P; Martin Conde MT; Alonso Grandes E; Lázaro López A; Morillo Verdugo R
Rev Esp Quimioter; 2024 Apr; 37(2):149-157. PubMed ID: 38240196
[TBL] [Abstract][Full Text] [Related]
3. Impact and acceptance of pharmacist-led interventions during HIV care in a third-level hospital in Spain using the Capacity-Motivation-Opportunity pharmaceutical care model: the IRAFE study.
Cantillana-Suárez MG; Robustillo-Cortés MLA; Gutiérrez-Pizarraya A; Morillo-Verdugo R
Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e157-e163. PubMed ID: 33627478
[TBL] [Abstract][Full Text] [Related]
4. Influence of CMO pharmaceutical care model-based intervention on readmission rate in high risk HIV patients: the INFARDAR study.
Guzmán Ramos MI; Manzano Garcia M; Robustillo-Cortés MA; Gutiérrez Pizarraya A; Morillo-Verdugo R
Rev Esp Quimioter; 2021 Oct; 34(5):459-467. PubMed ID: 34231351
[TBL] [Abstract][Full Text] [Related]
5. Application of CMO (capacity, motivation, and opportunity) methodology in pharmaceutical care to optimize the pharmacotherapy in older people living with HIV. DISPIMDINAC project.
Sánchez-Yáñez E; Huertas-Fernández MJ; Robustillo-Cortes MA; Ramos-Guerrero R; Fernández-Espínola S; Diaz-Acedo R; Montero-Martin V; Morillo-Verdugo R
Rev Esp Quimioter; 2023 Dec; 36(6):584-591. PubMed ID: 37724451
[TBL] [Abstract][Full Text] [Related]
6. Concurrent use of comedications reduces adherence to antiretroviral therapy among HIV-infected patients.
Cantudo-Cuenca MR; Jiménez-Galán R; Almeida-Gonzalez CV; Morillo-Verdugo R
J Manag Care Spec Pharm; 2014 Aug; 20(8):844-50. PubMed ID: 25062078
[TBL] [Abstract][Full Text] [Related]
7. Simplification and Multidimensional Adaptation of the Stratification Tool for Pharmaceutical Care in People Living With HIV.
Morillo-Verdugo R; Aguilar Pérez T; Gimeno-Gracia M; Rodríguez-González C; Robustillo-Cortes MLA;
Ann Pharmacother; 2023 Feb; 57(2):163-174. PubMed ID: 35707861
[TBL] [Abstract][Full Text] [Related]
8. Development of a risk stratification model for pharmaceutical care in HIV patients.
Morillo-Verdugo R; Martínez-Sesmero JM; Lázaro-López A; Sánchez-Rubio J; Navarro-Aznárez H; DeMiguel-Cascón M
Farm Hosp; 2017 May; 41(3):346-356. PubMed ID: 28478749
[TBL] [Abstract][Full Text] [Related]
9. Higher Risks of Virologic Failure and All-Cause Deaths Among Older People Living with HIV in Chongqing, China.
Wu G; Zhou C; Zhang X; Zhang W; Lu R; Ouyang L; Xing H; Shao Y; Ruan Y; Qian HZ
AIDS Res Hum Retroviruses; 2019; 35(11-12):1095-1102. PubMed ID: 31544479
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS.
Hirsch JD; Gonzales M; Rosenquist A; Miller TA; Gilmer TP; Best BM
J Manag Care Pharm; 2011 Apr; 17(3):213-23. PubMed ID: 21434698
[TBL] [Abstract][Full Text] [Related]
11. Comparison of adherence rates for antiretroviral, blood pressure, or mental health medications for HIV-positive patients at an academic medical center outpatient pharmacy.
Langness J; Cook PF; Gill J; Boggs R; Netsanet N
J Manag Care Spec Pharm; 2014 Aug; 20(8):809-14. PubMed ID: 25062074
[TBL] [Abstract][Full Text] [Related]
12. Application of the CMO methodology to the improvement of primary adherence to concomitant medication in people living with-HIV. The PRICMO Project.
Morillo-Verdugo R; Vélez-Díaz-Pallarés M; Fernández-Pacheco García-Valdecasas M; Fernández-Espínola S; Sánchez-Rubio Ferrández J; Navarro-Ruiz A
Farm Hosp; 2021 Jul; 45(5):247-252. PubMed ID: 34806584
[TBL] [Abstract][Full Text] [Related]
13. Patient Experience Evaluation of the CMO-Based Pharmaceutical Care Model vs Usual Care in People Living with HIV.
Morillo-Verdugo R; Lazaro-Lopez A; Alonso-Grandes E; Martin-Conde MT; Diaz-Ruiz P; Molina-Cuadrado E; Huertas-Fernandez MJ; Navarro-Aznares H; Areas Del Aguila V; Gimeno-Gracia M; Margusino-Framiñán L; Martínez-Sesmero JM
J Multidiscip Healthc; 2022; 15():2991-3003. PubMed ID: 36601427
[TBL] [Abstract][Full Text] [Related]
14. Influence of pharmacist intervention, based on CMO model, to improve activation in HIV patients.
Morillo-Verdugo R; Robustillo-Cortés MA; Manzano García M; Almeida-González CV
Rev Esp Quimioter; 2019 Feb; 32(1):40-49. PubMed ID: 30569694
[TBL] [Abstract][Full Text] [Related]
15. Influence of baseline characteristics and stratification level of patients living with HIV on pharmaceutical interventions developed according to the Capacity-Motivation-Opportunity methodology.
Cárdaba García ME; Pedraza Cezón LA; Andrés Rosado A; Contreras Macías E; Lorenzo Giménez S
Eur J Hosp Pharm; 2023 Jul; ():. PubMed ID: 37414516
[TBL] [Abstract][Full Text] [Related]
16. Immediate Antiretroviral Therapy Decreases Mortality Among Patients With High CD4 Counts in China: A Nationwide, Retrospective Cohort Study.
Zhao Y; Wu Z; McGoogan JM; Shi CX; Li A; Dou Z; Ma Y; Qin Q; Brookmeyer R; Detels R; Montaner JSG
Clin Infect Dis; 2018 Feb; 66(5):727-734. PubMed ID: 29069362
[TBL] [Abstract][Full Text] [Related]
17. Predictors of mortality among adult people living with HIV/AIDS on antiretroviral therapy at Suhul Hospital, Tigrai, Northern Ethiopia: a retrospective follow-up study.
Misgina KH; Weldu MG; Gebremariam TH; Weledehaweria NB; Alema HB; Gebregiorgis YS; Tilahun YG
J Health Popul Nutr; 2019 Nov; 38(1):37. PubMed ID: 31783924
[TBL] [Abstract][Full Text] [Related]
18. How have ART treatment programmes changed the patterns of excess mortality in people living with HIV? Estimates from four countries in East and Southern Africa.
Slaymaker E; Todd J; Marston M; Calvert C; Michael D; Nakiyingi-Miiro J; Crampin A; Lutalo T; Herbst K; Zaba B
Glob Health Action; 2014; 7():22789. PubMed ID: 24762982
[TBL] [Abstract][Full Text] [Related]
19. Mortality among people living with HIV on antiretroviral treatment in Bali, Indonesia: incidence and predictors.
Utami S; Sawitri AAS; Wulandari LPL; Artawan Eka Putra IWG; Astuti PAS; Wirawan DN; Causer L; Mathers B
Int J STD AIDS; 2017 Oct; 28(12):1199-1207. PubMed ID: 28201952
[TBL] [Abstract][Full Text] [Related]
20. Effect of baseline CD4 cell count at linkage to HIV care and at initiation of antiretroviral therapy on mortality in HIV-positive adult patients in Rwanda: a nationwide cohort study.
Nsanzimana S; Remera E; Kanters S; Forrest JI; Ford N; Condo J; Binagwaho A; Bucher H; Thorlund K; Vitoria M; Mills EJ
Lancet HIV; 2015 Sep; 2(9):e376-84. PubMed ID: 26423551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
